A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults

Primary Ciliary Dyskinesia Clinical Trial

Official title:

A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05685186
• Other study ID #: RCTAX001
• Status: Recruiting
• Start date: March 8, 2023
• Est. completion date: May 20, 2027

Study information

• Verified date: April 2023
• Source: ReCode Therapeutics
• Contact: Priya Ryali
• Phone: (650) 629-7900
• Email: clinicaltrials[@]recodetx.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values. Lung function, mucociliary clearance, radiological findings, and clinical findings will be assessed. Furthermore, quality of life will be assessed using QOL-PCD, a disease specific questionnaire.

Description:

Primary ciliary dyskinesia (PCD) is a rare, genetically heterogeneous disease characterized by progressive upper and lower respiratory tract infections and inflammation caused by impaired mucociliary clearance (MCC). While longitudinal studies of children and adolescents with PCD have informed the early natural history of lung disease, there remains a knowledge gap in disease characteristics and progression in adults. There are no prospective published data evaluating the natural history of airway morbidity and mortality in adults, and little is known about the optimal clinical measures and biomarkers to evaluate disease progression. Cohort studies are needed to understand clinical measures and biomarkers across the lifespan of people with PCD, distinguish disease subtypes, and define endpoint variability. Natural history studies are critical for designing future clinical trials. New therapies have lagged in part due to lack of clear clinical biomarkers for adults.

The overarching goal is to characterize clinical measures and biomarkers of airway disease in adults with PCD. In addition, a subset of these clinical measures and biomarkers will be collected in a group of healthy volunteers (HV) to establish normative values.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: May 20, 2027
• Est. primary completion date: December 20, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• PCD diagnosis with confirmation of 2 identified pathogenic genetic variants within 1 of the following ultrastructure variants:

• DNAI1 ODA defect

• Other ODA defect

• IDA - MTD defect

• RS defect

• Informed consent

Exclusion Criteria:

• Are a current smoker (e-cigarette, tobacco, or marijuana)

• Are a former smoker who discontinued smoking <1 year prior to enrollment or has a cumulative 1+ pack-year smoking history

• Have a recent stable forced expiratory volume in one second (FEV1) <35% predicted

• Have contraindications for MRI studies (implanted devices/materials; inability to tolerate; claustrophobia or severe anxiety that would preclude MRI/imaging)

• Have had a significant clinical radiation exposure (as determined by the investigator) within the past 6 months. Potential participants who have had a chest CT within the past 6 months may be eligible to be enrolled and their clinical CT will be utilized as the baseline for this study

• Are pregnant or breastfeeding

• Have any comorbidities likely to impact lung function (e.g., complex congenital heart disease, severe scoliosis, diseases involving immune dysregulation, lung transplantation, lung lobectomy, end-stage renal disease, or poor overall health status).

Related Conditions & MeSH terms

• Ciliary Motility Disorders
• Dyskinesias
• Primary Ciliary Dyskinesia

Intervention

Diagnostic Test:
• Spirometry
To assess lung function
• Multiple Breath Washout (MBW)
To measure Lung Clearance Index (LCI)
• Mucociliary Clearance (MCC)
To measure lung clearance after the inhalation of radiolabeled particles
• CT of the chest
Low radiation to assess structural lung disease
• MRI of the chest
To assess lung function and structural lung disease

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
ReCode Therapeutics	University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Descriptive Analysis	Descriptive statistical methods will be applied to analyze: lung function, measure % predicated (pp) FEV1. Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 52	From Baseline Through Week 52